INTRODUCTION {#s1}
============

Worldwide, cancer is currently the main cause of death and a public health problem that seriously threatens human health \[[@R1]\]. Biological and epidemiological studies have shown that carcinogenesis is a sophisticated, multivariate process resulting from interactions between genetic and environmental factors \[[@R2]\]. However, the exact mechanism of carcinogenesis has not been fully elucidated. Many aspects of malignant cancers, including carcinogenesis, aberrant growth, metastasis, and angiogenesis, have been attributed to reactive oxygen species (ROS) \[[@R3]\]. Such ROS-mediated damage to cellular macromolecules is thought to accumulate as a function of age, thus promoting carcinogenesis \[[@R4], [@R5]\].

Catalase (CAT) is an important endogenous antioxidant enzyme that decomposes hydrogen peroxide to oxygen and water, thus limiting the deleterious effects of ROS\[[@R6]\]; accordingly, the *CAT* gene may play an important role in substance metabolism. *CAT* is located on the nuclear chromosome 11p13, and polymorphisms in this gene have been reported to associate with the development of many types of cancer, such as invasive cervical cancer and prostate cancer \[[@R7]\].

The rs1001179 polymorphism (C-262T) is located in the promoter region of *CAT*, where it influences transcription factor binding and alters the basal transcription and consequent expression of the encoded enzyme \[[@R8]\]. The rs794316 polymorphism (A-15 T) has been identified in the promoter region near the *CAT* start site, and the endogenous variability of this promoter likely plays a role in the host response to oxidative stress \[[@R9]\]. A large number of previous studies in humans have suggested a possible correlation between genetic polymorphisms of CAT and susceptibility to cancers, such as prostate cancer \[[@R10]--[@R14]\], breast cancer \[[@R15]\], and hepatocellular carcinoma \[[@R16]--[@R19]\]. However, those studies published inconsistent results. Accordingly, we conducted a meta-analysis to combine data from all of the available case-control studies in order to validate the association of *CAT* polymorphisms with cancer risk.

RESULTS {#s2}
=======

Characteristics of included studies {#s2_1}
-----------------------------------

A flow chart of the study selection process is shown in Figure [1](#F1){ref-type="fig"}. Initially, 374 articles were identified. After reading the titles and abstracts of all the articles, 310 were excluded (164 articles were not related to cancer patients, 137 articles were not case-control studies and 9 articles were about other polymorphisms). After searching through the full texts of the remaining articles, an additional 15 were excluded, including 9 articles that contained no useful data and 6 articles that had re-reported data. Finally, a total of 37 studies from 29 published articles, involving 14,942 cases and 43,285 cancer-free controls, were included in this meta-analysis. The eligible studies presented data for several different cancer types, including prostate cancer, hepatocellular carcinoma, breast cancer, and colorectal cancer. Among these studies, 10 were based on Asian populations \[[@R9], [@R13], [@R15]--[@R17], [@R20]--[@R22]\], 20 on Caucasian populations \[[@R7], [@R10], [@R11], [@R14], [@R18], [@R23]--[@R33]\], 1 on an African population \[[@R14]\], and 6 on mixed-ethnicity populations \[[@R12], [@R19], [@R31], [@R34]--[@R36]\]. Furthermore, in 3 studies, the genotype distributions of the control groups departed from Hardy-Weinberg equilibrium (HWE) \[[@R7], [@R10], [@R20]\]. The characteristics of the eligible studies are presented in Table [1](#T1){ref-type="table"}.

![Flow diagram of included studies for the meta-analysis\
CNKI = China National Knowledge Infrastructure.](oncotarget-07-62954-g001){#F1}

###### Characteristics of the studies included in the meta-analysis

  First author   Year   Country       Ethnicity   Genotyping medthod   Source of control   Cancer type         Total sample size (case/control)   HWE        SNP
  -------------- ------ ------------- ----------- -------------------- ------------------- ------------------- ---------------------------------- ---------- -----------
  Sousa          2016   Brazil        Mixed       Taqman               hospital            HCC                 106/139                            0.44       rs1001179
  Castaldo       2015   Portugal      Caucasian   PCR                  population          CC                  119/106                            **0.00**   rs1001179
  Geybels        2015   Netherland    Caucasian   PCR                  population          PC                  1529/25184                         **0.00**   rs1001179
  Liu            2015   China         Asian       PCR-RFLP             hospital            HCC                 266/248                            0.68       rs1001179
  Saadat         2015   Iran          Caucasian   PCR                  population          BC                  407/395                            0.40       rs1001179
  Su-1           2015   China         Asian       PCR-RFLP             hospital            HCC                 301/186                            0.49       rs1001179
  Su-2           2015   China         Asian       PCR-RFLP             hospital            HCC                 99/294                             0.83       rs1001179
  Banescu        2014   Romania       Caucasian   PCR-RFLP             population          CML                 168/321                            0.47       rs1001179
  Aynali         2013   Turkey        Caucasian   PCR-RFLP             hospital            Laryngeal cancer    25/23                              0.13       rs1001179
  Tefik          2013   Turkey        Caucasian   PCR-RFLP             population          PC                  155/195                            0.07       rs1001179
  Ding           2012   China         Asian       PCR                  population          PC                  1417/1008                          0.86       rs1001179
  Farawela       2012   Egypt         Caucasian   PCR-RFLP             population          NHL                 100/100                            0.49       rs1001179
  Karunasinghe   2012   New Zealand   Mixed       Taqman               population          PC                  258/567                            0.42       rs1001179
  Tsai           2012   Taiwan        Asian       PCR                  hospital            BC                  260/224                            0.44       rs1001179
  Chang          2012   China         Asian       PCR-RFLP             population          CRC                 880/848                            **0.00**   rs794316
  Nahon          2011   France        Caucasian   Taqman               hospital            HCC                 84/55                              0.62       rs1001179
  Ezzikouri      2010   France        Mixed       PCR-RFLP             population          HCC                 96/222                             0.59       rs1001179
  He-1           2010   USA           Caucasian   Taqman               population          BCC                 270/796                            0.89       rs1001179
  He-2           2010   USA           Caucasian   Taqman               population          Melanoma            211/796                            0.89       rs1001179
  He-3           2010   USA           Caucasian   Taqman               population          SCC                 266/796                            0.89       rs1001179
  Tang           2010   USA           Mixed       Taqman               population          Pancreatic cancer   551/602                            0.97       rs1001179
  Wu             2010   Taiwan        Asian       PCR-RFLP             hospital            OCC                 122/122                            0.18       rs794316
  Funke          2009   Germany       Caucasian   PCR                  population          CRC                 632/605                            0.11       rs1001179
  Li             2009   USA           Caucasian   Taqman               population          BC                  497/493                            1.00       rs1001179
  Quick-1        2008   USA           Caucasian   HM L/I MS            population          BC                  569/974                            0.70       rs1001179
  Quick-2        2008   USA           Mixed       HM L/I MS            population          BC                  47/108                             0.22       rs1001179
  Rajaraman-1    2008   USA           Caucasian   Taqman               hospital            Glioma              330/438                            0.57       rs1001179
  Rajaraman-2    2008   USA           Caucasian   Taqman               hospital            Meningioma          120/438                            0.57       rs1001179
  Rajaraman-3    2008   USA           Caucasian   Taqman               hospital            Acoustic neuroma    63/438                             0.57       rs1001179
  Choi-1         2007   USA           Caucasian   HM L/I MS            population          PC                  463/1233                           0.26       rs1001179
  Choi-2         2007   USA           African     HM L/I MS            population          PC                  27/120                             0.60       rs1001179
  Cebrian        2006   UK            Caucasian   Taqman               population          BC                  2171/2262                          0.96       rs1001179
  Ho             2006   China         Asian       PCR-RFLP             hospital            LC                  230/240                            0.44       rs1001179
  Lightfoot      2006   USA/UK        Mixed       Taqman               population          NHL                 909/1437                           0.96       rs1001179
  Ahn            2005   USA           Caucasian   HM L/I MS            population          BC                  1008/1056                          0.93       rs1001179
  Lee-1          2002   South Korea   Asian       PCR-RFLP             population          GC                  80/108                             0.47       rs794316
  Lee-2          2002   South Korea   Asian       PCR-RFLP             population          HCC                 106/108                            0.47       rs794316

PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; HM L/I MS: high-throughput, matrixassisted, laser desorption/ionization time-of-flight mass spectrometry; HCC: hepatocellular carcinoma; CC: cervical cancer; BC: breast cancer; CML: chronic myeloid leukemia; NHL: non-Hodgkin lymphoma; BCC: basal cell carcinoma; SCC: squamous cell carcinoma; PC: Prostate cancer; CRC: colorectal cancer; OCC: Oral cavity cancer; GC: gastric cancer; LC: lung cancer; SNP: single-nucleotide polymorphisms; HWE: Hardy-Weinberg equilibrium.

Meta-analysis of *CAT* polymorphisms and cancer risk {#s2_2}
----------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, the minor allele frequencies varied widely among cancer patients across the eligible studies, ranging from 0.04 to 0.50 for rs1001179 polymorphism and 0.31 to 0.43 for rs794316 polymorphism. The average minor allele frequencies for these polymorphisms were 0.19 and 0.40, respectively.

###### Genotype Distribution and Allele Frequency of CAT polymorphisms in Cases and Controls

  First author        Genotype (N)   Allele frequency (N)   MAF                                                                    
  ------------------- -------------- ---------------------- ----- ----- ------- ------- ------ ------ ------ ----- ------- ------- ------
  rs1001179                                                                                                                        
  Sousa 2016          106            68                     35    3     139     103     32     4      171    41    238     40      0.19
  Castaldo 2015       119            58                     25    36    106     65      27     14     141    97    157     55      0.41
  Geybels 2015        1529           887                    539   103   25184   15794   8108   1282   2313   745   39696   10672   0.24
  Liu 2015            266            239                    27    0     248     223     24     1      505    27    470     26      0.05
  Saadat 2015         407            261                    129   17    395     240     132    23     651    163   612     178     0.20
  Su-1 2015           301            273                    27    1     186     168     18     0      573    29    354     18      0.05
  Su-2 2015           99             92                     7     0     294     264     29     1      191    7     557     31      0.04
  Banescu 2014        168            105                    49    14    321     168     132    21     259    77    468     174     0.23
  Aynali 2013         25             13                     10    2     23      12      11     0      36     14    35      11      0.28
  Tefik 2013          155            58                     64    33    195     107     68     20     180    130   282     108     0.42
  Ding 2012           1417           1316                   99    2     1008    940     67     1      2731   103   1947    69      0.04
  Farawela 2012       100            26                     49    25    100     28      53     19     101    99    109     91      0.50
  Karunasinghe 2012   258            144                    99    15    567     350     195    22     387    129   895     239     0.25
  Tsai 2012           260            225                    35    0     224     202     22     0      485    35    426     22      0.07
  Nahon 2011          84             62                     21    1     55      32      19     4      145    23    83      27      0.14
  Ezzikouri 2010      96             76                     14    6     222     173     45     4      166    26    391     53      0.14
  He-1 2010           270            161                    97    12    796     512     252    32     419    121   1276    316     0.22
  He-2 2010           211            129                    75    7     796     512     252    32     333    89    1276    316     0.21
  He-3 2010           266            160                    96    10    796     512     252    32     416    116   1276    316     0.22
  Tang 2010           551            349                    174   28    602     366     207    29     872    230   939     265     0.21
  Funke 2009          632            374                    235   23    605     348     231    26     983    281   927     283     0.22
  Li 2009             497            295                    176   26    493     303     167    23     766    228   773     213     0.23
  Quick-1 2008        569            345                    197   27    974     598     333    43     887    251   1529    419     0.22
  Quick-2 2008        47             34                     13    0     108     97      10     1      81     13    204     12      0.14
  Rajaraman-1 2008    330            195                    124   11    438     251     164    23     514    146   666     210     0.22
  Rajaraman-2 2008    120            73                     39    8     438     251     164    23     185    55    666     210     0.23
  Rajaraman-3 2008    63             43                     17    3     438     251     164    23     103    23    666     210     0.18
  Choi-1 2007         463            281                    157   25    1233    732     445    56     719    207   1909    557     0.22
  Choi-2 2007         27             24                     3     0     120     109     11     0      51     3     229     11      0.06
  Cebrian 2006        2171           1351                   707   113   2262    1362    787    113    3409   933   3511    1013    0.21
  Ho 2006             230            209                    19    2     240     217     23     0      437    23    457     23      0.05
  Lightfoot 2006      909            554                    298   57    1437    867     498    72     1406   412   2232    642     0.23
  Ahn 2005            1008           614                    349   45    1056    679     335    42     1577   439   1693    419     0.22
  rs794316                                                                                                                         
  Chang 2012          880            280                    448   152   848     272     472    104    1008   752   1016    680     0.43
  Wu 2010             122            57                     55    10    122     62      54     6      169    75    178     66      0.31
  Lee-1 2002          80             35                     38    7     108     51      44     13     108    52    146     70      0.33
  Lee-2 2002          106            51                     42    13    108     51      44     13     144    68    146     70      0.32

A: the major allele; B: the minor allele; MAF: minor allele frequencies.

The main results of this meta-analysis are listed in Table [3](#T3){ref-type="table"}. Thirty-three studies involving 13,754 cases and 42,099 controls were included for rs1001179. As shown in Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}, we observed an increased cancer risk associated with the rs1001179 polymorphism under the homozygote and recessive models (TT *vs*. CC: odds ratio \[OR\] = 1.19, 95% confidence interval \[CI\] = 1.04-1.37, *P* = 0.01; TT *vs*. CT+CC: OR = 1.19, 95% CI = 1.06- 1.34, *P* \< 0.001.) In the cancer-specific analysis, the results showed significant correlations between the rs1001179 polymorphism and prostate cancer risk in different comparison models (T *vs*. C: OR = 1.21, 95% CI = 1.04-1.41, *P* = 0.02; TT *vs*. CC: OR = 1.57, 95% CI = 1.17-2.10, *P* = 0.00; TT+CT *vs*. CC: OR = 1.20, 95% CI = 1.01-1.42, *P* = 0.04; TT *vs*. CT+CC: OR = 1.40, 95% CI = 1.18-1.67, *P* \< 0.001). However, no meaningful correlations were observed in analyses stratified by ethnicity or the source of controls.

###### Meta-analysis of the association between CAT polymorphisms and cancer risk

  Comparisons         OR         95%CI            *P* value   Heterogeneity   Effects model   
  ------------------- ---------- ---------------- ----------- --------------- --------------- ---
  **B *vs* A**                                                                                
  rs1001179           1.06       0.99-1.13        0.11        54%             0.00            R
  HWE                 1.04       0.97-1.11        0.28        39%             0.02            R
  Caucasian           1.05       0.96-1.14        0.27        66%             0.00            R
  Asian               1.05       0.86-1.29        0.64        0%              0.80            F
  Mixed               1.10       0.92-1.32        0.29        54%             0.07            R
  PC                  **1.21**   **1.04-1.41**    0.02        61%             0.02            R
  HCC                 0.85       0.62-1.17        0.32        25%             0.25            F
  BC                  1.04       0.93-1.17        0.50        52%             0.05            R
  rs794316            1.10       0.98-1.24        0.11        0%              0.88            F
  HWE                 1.06       0.84- 1.35       0.61        0%              0.76            F
  **BB *vs* AA**                                                                              
  rs1001179           **1.20**   **1.08-1.34**    0.00        20%             0.16            F
  HWE                 **1.12**   **1.00-1.27**    0.05        0%              0.70            F
  Caucasian           1.16       0.97-1.38        0.10        41%             0.03            R
  Asian               1.37       0.37-5.14        0.64        0%              0.80            F
  Mixed               1.29       0.98-1.68        0.07        0%              0.47            F
  PC                  **1.57**   **1.17- 2.10**   0.00        33%             0.20            F
  HCC                 0.88       0.20- 3.82       0.87        45%             0.12            F
  BC                  1.03       0.85- 1.25       0.75        0%              0.82            F
  rs794316            **1.34**   **1.03-1.74**    0.00        0%              0.58            F
  HWE                 1.09       0.62-1.91        0.76        0%              0.52            F
  **AB *vs* AA**                                                                              
  rs1001179           1.02       0.94- 1.09       0.68        39%             0.01            R
  HWE                 1.01       0.93- 1.09       0.82        35%             0.03            R
  Caucasian           1.01       0.93- 1.11       0.76        47%             0.01            R
  Asian               1.03       0.84- 1.28       0.77        0%              0.77            F
  Mixed               1.05       0.80- 1.38       0.72        67%             0.02            R
  PC                  1.14       0.99- 1.31       0.06        33%             0.19            F
  HCC                 0.81       0.60- 1.09       0.17        0%              0.73            F
  BC                  1.07       0.91- 1.25       0.43        60%             0.02            R
  rs794316            0.97       0.81- 1.16       0.74        0%              0.76            F
  HWE                 1.10       0.79- 1.52       0.59        0%              0.81            F
  **BB+AB *vs* AA**                                                                           
  rs1001179           1.04       0.96- 1.12       0.33        48%             0.00            R
  HWE                 1.02       0.95- 1.11       0.54        39%             0.02            R
  Caucasian           1.03       0.94- 1.14       0.50        59%             0.00            R
  Asian               1.04       0.84- 1.29       0.70        0 %             0.79            F
  Mixed               1.09       0.86- 1.38       0.49        62%             0.03            R
  PC                  **1.20**   **1.01- 1.42**   0.04        55%             0.05            R
  HCC                 0.83       0.62- 1.11       0.21        0%              0.56            F
  BC                  1.06       0.91- 1.23       0.44        59%             0.02            R
  rs794316            1.04       0.87-1.23        0.68        0%              0.92            F
  HWE                 1.10       0.80- 1.49       0.57        0%              0.85            F
  **BB *vs* AB+AA**                                                                           
  rs1001179           **1.19**   **1.06- 1.34**   0.00        10%             0.31            F
  HWE                 **1.12**   **1.00- 1.27**   0.05        0%              0.70            F
  Caucasian           1.16       0.99- 1.35       0.06        29%             0.11            F
  Asian               1.38       0.37- 5.18       0.63        0 %             0.80            F
  Mixed               1.30       0.99- 1.70       0.05        0%              0.50            F
  PC                  **1.40**   **1.18- 1.67**   0.00        0%              0.48            F
  HCC                 0.95       0.23- 3.99       0.94        43%             0.14            F
  BC                  1.04       0.86- 1.25       0.70        0%              0.89            F
  rs794316            **1.39**   **1.09-1.77**    0.01        0%              0.41            F
  HWE                 1.05       0.61- 1.79       0.87        0%              0.46            F

A: the major allele; B: the minor allele; F: fixed effects mode; R: random effects model; HCC: hepatocellular carcinoma; BC: breast cancer; PC: Prostate cancer; HWE: meta-analysis excluding the studies departing from HWE.

![Forest plot of cancer risk related to rs1001179 polymorphism under TT versus CC genetic model\
T = the minor allele in rs1001179 polymorphism, C = the major allele in rs1001179 polymorphism, CI = confidence interval, OR = odds ratio.](oncotarget-07-62954-g002){#F2}

The association of the rs794316 polymorphism with cancer risk was investigated in 4 studies involving 1,188 cases and 1,186 controls. This polymorphism was associated with an increased cancer risk in the overall population under the two models (TT *vs*. AA: OR = 1.34, 95% CI = 1.03-1.74, *P* \< 0.001; TT *vs*. AT+AA: OR = 1.39, 95% CI = 1.09-1.77, *P* = 0.01; Figure [3](#F3){ref-type="fig"}).

![Forest plot of cancer risk related to rs794316 polymorphism under TT versus AA genetic model\
T = the minor allele in rs794316 polymorphism, A = the major allele in rs794316 polymorphism, CI = confidence interval, OR = odds ratio.](oncotarget-07-62954-g003){#F3}

Heterogeneity analysis and publication bias {#s2_3}
-------------------------------------------

In this meta-analysis, Q-statistic test was used to detect between-study heterogeneity that arose from methodological or clinical dissimilarity across studies. When the P value of the heterogeneity test was more than 0.1 (P ≥0.1), a fixed-effects model was performed. Otherwise, the random-effects model was used. To explore the other factors which may influence our results, we performed a meta-regression analysis. As shown in the Table [4](#T4){ref-type="table"}, sample size was not the factor which could be involved in cancer susceptibility (*P* = 0.134). Furthermore, the results revealed that the publication year, ethnicity, genotype method and the source of controls were all not the factors that could impact on our results (*P* = 0.088, 0.368, 0.676 and 0.300, respectively). We also performed a funnel plot and Egger\'s test to assess publication bias. As shown in Figure [4](#F4){ref-type="fig"}, the funnel plots failed to reveal any obvious asymmetries of the 2 polymorphisms in the overall population, and the results of Egger\'s test revealed no publication bias (*P* \> 0.05). Therefore, the results revealed that publication bias was not significant in this meta-analysis.

###### Meta-regression analyses of potential source of heterogeneity

  Heterogeneity factors   Coefficient   SE      Z       *P*     95% CI   
  ----------------------- ------------- ------- ------- ------- -------- -------
  Sample size             0.047         0.042   1.12    0.273   −0.039   0.134
  Publication year        0.026         0.014   1.77    0.088   −0.004   0.056
  Ethnicity               0.146         0.159   0.92    0.368   −0.182   0.473
  Genotype method         −0.023        0.054   −0.42   0.676   −0.135   0.089
  Source of control       0.259         0.244   1.06    0.300   −0.244   0.761

SE: standard error; 95% CI: 95% confidence interval; LL: lower limit; UL: upper limit.

![Begg\'s funnel plot for publication bias test of CAT polymorphisms: rs1001179 (A), rs794316 (B), under the homozygous model](oncotarget-07-62954-g004){#F4}

Sensitivity analysis {#s2_4}
--------------------

A single study was deleted one at a time from the meta-analysis to reflect the influence of each individual dataset on the pooled ORs. The analysis results demonstrated that no single study greatly influenced the overall cancer risk estimations with respect to the *CAT* polymorphisms (Figure [5](#F5){ref-type="fig"}), which indicates that our results are statistically robust.

![Sensitivity analysis of the association between CAT rs1001179 polymorphism and cancer risk under the homozygous model](oncotarget-07-62954-g005){#F5}

DISCUSSION {#s3}
==========

Previous case-control studies have investigated the association between the rs1001179 polymorphism and cancer risk. No significant associations were observed between rs1001179 polymorphism and hepatocellular carcinoma or breast cancer risk in studies by Liu et al. \[[@R17]\] and Saadat et al. \[[@R23]\], respectively. However, Geybels et al. \[[@R10]\] and Castaldo et al.\[[@R7]\] reported significant associations between rs1001179 polymorphism and increased prostate and cervical cancer risks, respectively, and Nahon et al. \[[@R18]\] and Su et al. \[[@R16]\] demonstrated that rs1001179 polymorphism was a protective factor with respect to hepatocellular carcinoma susceptibility.

We combined all the case-control studies concerning rs1001179 polymorphism and cancer risk to perform this meta-analysis, and found that individuals harboring the rs1001179 TT and rs794316 TT genotypes had a higher cancer risk than did those with other genotypes. This is likely attributable to the relationship between rs1001179 polymorphism and lower *CAT* activity, which further hinders the response to oxidative stress and might lead to tumorigenesis \[[@R37], [@R38]\]. The stratified analysis results indicated that the *CAT* rs1001179 polymorphism was only associated with prostate cancer, but not other cancers. These results were in accordance with others\' findings. Geybels et al. observed that the *CAT* rs1001179 polymorphism was associated with the risk of stage III/IV prostate cancer, which might be explained by the effect of *CAT* expression on oxidative stress and the link between increased oxidative stress and prostate cancer.

A previous meta-analysis including 9,777 cancer patients and 12,223 controls showed significant association between rs1001179 polymorphism and cancer risk in the recessive model \[[@R39]\]. Compared with that meta-analysis, our meta-analysis included 11 new independent studies of hepatocellular carcinoma \[[@R16], [@R17], [@R22], [@R34]\], chronic myeloid leukemia \[[@R24]\], laryngeal cancer \[[@R25]\], colorectal cancer \[[@R20]\], and oral cavity cancer \[[@R9]\]. Different from the previous result, we observed an association between the rs1001179 polymorphism and an increased cancer risk in the homozygote model. And it is worth mentioning that we found an association of the rs794316 polymorphism with cancer risk in recessive model and homozygote model, which wasn\'t detected by anyone before.

Because the control group genotype distributions departed from HWE in 3 studies, we performed a subgroup analysis that excluded those studies. Regarding the rs1001179 polymorphism, the result was remained consistent with the overall analysis; in other words, an association between an increased cancer risk and rs1001179 polymorphism was observed in recessive model and homozygote model. Nevertheless, we observed no significant association between the rs794316 polymorphism and cancer risk with any of the genetic models, although this might be a consequence of the small number of studies.

Several limitations of this meta-analysis should be acknowledged. First, only Asian population was involved in the analysis of rs794316, and most studies of rs1001179 are for Caucasian and Asian population. Accordingly, it would be better to include more studies with various ethnic groups to identify their definite roles in different populations. Second, some detailed information (e.g., sex, age, lifestyle, and environmental factors) was not considered. Third, the overall outcomes were based on individual unadjusted ORs, whereas a more precise evaluation should be adjusted using other potentially suspect factors. Fourth, the genotyping methods used in the eligible studies differed widely, which might have influenced the results. Moreover, although we have summarized all data on rs794316 polymorphism and cancer risk, the number of relative studies still needs further expansion.

In summary, this meta-analysis has shown associations of the *CAT* rs1001179 and rs794316 polymorphisms with an increased cancer risk. Additional larger-scale multicenter studies with larger sample sizes are needed to further validate the possible roles of these polymorphisms in cancers.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

The PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI) databases were searched for publications from 2002 to January 2016 using the terms "cancer" or "tumor", "CAT" or "Catalase", "polymorphism" or "SNP", "rs1001179" or "C-262T", and "rs794316" or "A-15 T". We also used the "Related Articles" option in PubMed to identify additional studies of the same topic. The reference lists of the retrieved articles were also screened. All included studies were selected using the following criteria: (a) studies must have featured a case-control design and focused on *CAT* polymorphism and cancer risk; (b) published data must have been sufficient to allow OR estimation with a 95% CI; and (c) for multiple publications reporting the same data or overlapping data, the largest or most recent publication was selected.

Data extraction {#s4_2}
---------------

Initially, 2 investigators (Liu K and Liu XH) independently checked all potentially relevant studies, and disagreements were resolved through discussions with a third researcher. We extracted the following items from each article: first author, year of publication, country of origin, ethnicity, cancer types, control source, genotyping method, total numbers of cases and controls, and numbers of different genotypes among cases and controls. All data were extracted from published articles. All cancers were confirmed by histology or pathology. The non-cancer controls had no evidence of any malignant disease at the time of the study.

Statistical analysis {#s4_3}
--------------------

We used ORs and 95% CIs to evaluate the cancer risks associated with *CAT* polymorphisms. Heterogeneity between studies was evaluated using the I^2^ test, with a higher I^2^ value indicating a higher level of heterogeneity (I^2^ = 75-100%: extreme heterogeneity; I^2^ = 50-75%: great heterogeneity; I^2^ = 25-50%: moderate heterogeneity; I^2^ \< 25%: no heterogeneity). During the heterogeneity evaluation, the fixed-effects model would be used if the P value was ≥0.10; otherwise, the random-effects model was used. Subgroup analyses were performed according to cancer type, control source, and ethnicity. A sensitivity analysis was performed to assess the stability of the final results by sequentially omitting each individual study at a time. Egger\'s test and Begg\'s test were adopted to assess publication bias. The meta-analysis assessed the following genetic models: dominant model (AB+BB *vs*. AA), recessive model (BB *vs*. AA + AB), homozygote comparison (BB *vs*. AA), heterozygote comparison (AB *vs*. AA), and allele comparison (B *vs*. A). All analyses were performed using the Stata software, version 12.0 (Stata Corp., College Station, TX, USA). A P value \< 0.5 was considered statistically significant, and all P values were 2-sided.
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